167 related articles for article (PubMed ID: 38757726)
21. Targeting NAD
Kennedy BE; Sadek M; Elnenaei MO; Reiman A; Gujar SA
Trends Cancer; 2020 Jan; 6(1):9-12. PubMed ID: 31952784
[TBL] [Abstract][Full Text] [Related]
22. CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers.
Jiao Y; Yi M; Xu L; Chu Q; Yan Y; Luo S; Wu K
Expert Opin Investig Drugs; 2020 Nov; 29(11):1295-1308. PubMed ID: 32822558
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
van de Donk NW; Moreau P; Plesner T; Palumbo A; Gay F; Laubach JP; Malavasi F; Avet-Loiseau H; Mateos MV; Sonneveld P; Lokhorst HM; Richardson PG
Blood; 2016 Feb; 127(6):681-95. PubMed ID: 26631114
[TBL] [Abstract][Full Text] [Related]
24. Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.
Steinhardt MJ; Zhou X; Krummenast F; Meckel K; Nickel K; Böckle D; Messerschmidt J; Knorz S; Dierks A; Heidemeier A; Lapa C; Einsele H; Rasche L; Kortüm KM
Int J Immunopathol Pharmacol; 2020; 34():2058738420980258. PubMed ID: 33353443
[TBL] [Abstract][Full Text] [Related]
25. Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2559. PubMed ID: 30459772
[TBL] [Abstract][Full Text] [Related]
26. Isatuximab for the treatment of multiple myeloma.
Goldsmith SR; Liu L; Covut F
Drugs Today (Barc); 2021 Nov; 57(11):665-675. PubMed ID: 34821880
[TBL] [Abstract][Full Text] [Related]
27. Application of CD38 monoclonal antibody in kidney disease.
Chen Z; Xu Q; Shou Z
Front Immunol; 2024; 15():1382977. PubMed ID: 38799465
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
van de Donk NW; Janmaat ML; Mutis T; Lammerts van Bueren JJ; Ahmadi T; Sasser AK; Lokhorst HM; Parren PW
Immunol Rev; 2016 Mar; 270(1):95-112. PubMed ID: 26864107
[TBL] [Abstract][Full Text] [Related]
29. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
[No Abstract] [Full Text] [Related]
30. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
Zamagni E; Tacchetti P; Pantani L; Cavo M
Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
[TBL] [Abstract][Full Text] [Related]
31. The CD38
Sarkar S; Chauhan SKS; Daly J; Natoni A; Fairfield H; Henderson R; Nolan E; Swan D; Hu J; Reagan MR; O'Dwyer M
Cancer Immunol Immunother; 2020 Mar; 69(3):421-434. PubMed ID: 31919623
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
33. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Kassem S; Diallo BK; El-Murr N; Carrié N; Tang A; Fournier A; Bonnevaux H; Nicolazzi C; Cuisinier M; Arnould I; Sidhu SS; Corre J; Avet-Loiseau H; Teillaud JL; van de Velde H; Wiederschain D; Chiron M; Martinet L; Virone-Oddos A
Blood; 2022 Feb; 139(8):1160-1176. PubMed ID: 35201323
[TBL] [Abstract][Full Text] [Related]
34. Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab.
Shen F; Shen W
Technol Cancer Res Treat; 2022; 21():15330338221106563. PubMed ID: 35903924
[TBL] [Abstract][Full Text] [Related]
35. Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials.
Ye W; Wu X; Liu X; Zheng X; Deng J; Gong Y
BMC Cancer; 2021 Sep; 21(1):994. PubMed ID: 34488679
[TBL] [Abstract][Full Text] [Related]
36. Daratumumab for the treatment of multiple myeloma.
Touzeau C; Moreau P
Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
[TBL] [Abstract][Full Text] [Related]
37. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
[TBL] [Abstract][Full Text] [Related]
38. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
39. CD38 as an immunotherapeutic target in multiple myeloma.
Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F
Expert Opin Biol Ther; 2018 Dec; 18(12):1209-1221. PubMed ID: 30394809
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
García-Guerrero E; Götz R; Doose S; Sauer M; Rodríguez-Gil A; Nerreter T; Kortüm KM; Pérez-Simón JA; Einsele H; Hudecek M; Danhof S
Leukemia; 2021 Jan; 35(1):201-214. PubMed ID: 32350373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]